

Review

VHL and Hypoxia Signaling: Beyond HIF in Cancer

Jing Zhang ^{1,*} and **Qing Zhang** ^{1,2,*} ¹ Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC-Chapel Hill, Chapel Hill, NC 27599, USA² Department of Pharmacology, UNC-Chapel Hill, Chapel Hill, NC 27599, USA* Correspondence: jingzha@email.unc.edu (J.Z.); qing_zhang@med.unc.edu (Q.Z.);
Tel.: +1-919-843-7887 (Q.Z.)

Received: 24 February 2018; Accepted: 16 March 2018; Published: 19 March 2018

Abstract: Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1 α and HIF2 α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF- κ B signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

Keywords: VHL; Hypoxia; ccRCC

1. Introduction

The incidence of kidney cancer has been increasing for decades, causing 134,000 deaths annually worldwide and accounting for an estimated 62,700 new cases as well as 14,240 deaths in the United States of America (USA) in 2016 [1–3]. Clear cell carcinoma of renal cancer (ccRCC) makes up approximately 70% of all renal malignancies and harbors up to 92% of Von Hippel-Lindau (VHL) inactivation [2,4–7]. Despite a significant mutation heterogeneity within ccRCC, VHL inactivation occurs ubiquitously across all tumor regions [2,8]. VHL is a tumor suppressor in ccRCC that regulates its substrates by forming a complex with elongins B and C (termed “VBC”), which are key components of an E3 ubiquitin ligase complex that is crucial for VHL function [9–12]. It is well known that this E3 ligase complex targets hypoxia inducible factor α (HIF α , including HIF1 α and HIF2 α) for ubiquitination and degradation, which contributes substantially to the transforming phenotype of renal cancer [13,14]. Further research has shown that VHL interacts with HIF1 α through the hydroxylation of defined HIF1 α proline residues (prolines 402 and 564) by members of the EGLN family of iron- and 2-oxoglutarate-dependent dioxygenases (EGLN1, EGLN2, and EGLN3) [15]. Therefore, the loss of VHL leads to HIF α accumulation and translocation into the nucleus, which subsequently activates the transcription of HIF target genes that are involved in critical oncogenic pathways, including angiogenesis (e.g., Vascular endothelial growth factor ((VEGF)), glycolysis and glucose transport (e.g., Glucose transporter type I (GLUT1)), and erythropoiesis (e.g., Erythropoietin (EPO)) [16–20]. Advances in HIF regulation have been recently reviewed extensively by Choudhry et al. [21].

Although the degradation of HIF α is important for the tumor suppressor function of VHL, growing evidence suggests that additional VHL substrates exist. For example, the existence of uncharacterized VHL substrates other than HIF may account for different subtypes of VHL disease (Type 2A, 2B versus 2C) [22–24]. The VHL-mediated assembly of intercellular junctions is through HIF-independent mechanisms in VHL-deficient ccRCC [25]. Also, the AKT, the Notch signaling

cascade, and the NF- κ B signaling pathway are constitutively active upon *VHL* loss in ccRCC [26–28]. Our colleagues have reviewed these recently identified *VHL* substrates/binding partners extensively elsewhere [29]. In this review, we focus on *VHL*-regulated signaling pathways involving newly identified substrates/binding partners that may play important roles in hypoxia signaling beyond HIF.

2. Hypoxia/*VHL* and Lactate–NDRG3–Raf–ERK Axis

Lee et al. identified NDRG3 as a substrate of EglN1/VHL through Flag-mediated immunoprecipitation of EglN1, followed by mass spectrometry. Under normoxia, NDRG3 is ubiquitinated and degraded via the EglN1-VHL signaling pathway. NDRG3 accumulates under hypoxia by binding to lactate, and further interacts with c-Raf for the activation of the Raf-ERK pathway, thereby contributing to hypoxic cell growth and angiogenesis. NDRG3 remains very stable once it is bound to lactate, even when cells are reoxygenated, which suggests that lactate–NDRG3–Raf–ERK axis-induced responses contribute to the maintenance of tumor progression under prolonged hypoxic conditions. This study identified NDRG3 as the hypoxia-inducible lactate sensor that provides crucial hypoxia signaling of oxygen-dependent regulation in an HIF-independent manner; therefore, a combinatorial targeting of both HIF and NDRG3 might be a highly effective therapy in cancer [30,31].

It is important to point out that this study provides an additional model (besides the ROS–EglN–HIF axis) of wiring metabolism to signal the transduction cascade for downstream gene regulation and corresponding cell responses. Altered metabolism is one of the hallmarks of cancer, with the underlying mechanism potentially revealing the vulnerability of the cancer [32,33]. The abundance of nutrients (e.g., glucose, glutamine, and lipid) fluctuates significantly along with oxygen availability or *VHL* status [34]. For example, Hakimi et al. deciphered the metabolic atlas of ccRCC by using metabolomics profiling, and characterized broad shifts in the central carbon metabolism, the one-carbon metabolism, and the antioxidant response in ccRCC patients [35]. Therefore, how these altered metabolic pathways are wired to regulate cellular adaptation to the harsh tumor growth environment needs to be further investigated in the future.

3. Hypoxia/*VHL*–AKT–mTOR Axis

PI3K/AKT/mTOR signaling is a well-established cell growth regulatory pathway. AKT phosphorylation at Thr308 and Ser473 increases its kinase activity to stimulate its downstream mTORC1 activation, leading to an increase in the activity of various anabolic, biosynthetic pathways for cell growth and proliferation [36]. The PI3K/AKT/mTOR pathway is altered with hypoxia/*VHL*. For example, Polytarchou et al. reported that the AKT pathway is activated in hypoxic conditions, which promotes tumor resistance to hypoxia through the induction of miR-21 [37]. Phosphorylated, active AKT is recruited to mitochondria under hypoxic conditions, whereby PDK1 is phosphorylated at T346, which switches tumor metabolism to glycolysis and maintains the redox balance needed for tumor cell survival and proliferation [38]. Guo et al. showed that AKT is activated to promote tumorigenesis in cells that lack oxygen or functional *VHL*. This was a mechanistic study that demonstrated that *VHL* binds to hydroxylated AKT induced by EglN1 and inhibits its phosphorylation and kinase activity in an HIF-independent and prolyl-hydroxylation-dependent fashion. Collectively, the intersection between hypoxia/*VHL* and AKT signaling involves multiple steps, including microRNA regulation, subcellular compartment change, and post-translational regulation (hydroxylation). Recently, Zhang et al. revealed a pan-cancer proteogenomic atlas for PI3K/AKT/mTOR changes across over 10,000 human cancers, supporting the notion that *VHL* mutations are associated with highly active AKT/mTOR signaling [39]. These studies provide the therapeutic strategy of targeting PI3K/AKT/mTOR in *VHL*-deficient ccRCC and in hypoxic tumors to overcome drug resistance.

Indeed, two Food and Drug Administration (FDA)-approved mTOR inhibitors, temsirolimus and everolimus, showed improved clinical outcomes and provided additional options for difficult-to-treat cancers. As the targeted therapies are growing so rapidly, an urgent challenge is how to design the most effective combinatory treatments to prevent the emergence of escape mechanisms [2,3].

4. VHL–NF-κB Axis

NF-κB is one of the key regulators of inflammation. The NF-κB family, as a transcription factor, consists of p65 (RelA), c-Rel, RelB, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). In a resting cell, they exist as homodimers or heterodimers preferentially bound to the IκB family, which prevents DNA-binding by NF-κB activation. Extracellular or intracellular signals initiate NF-κB activation, such as pro-inflammatory cytokines (e.g., tumor necrosis factor (TNF)), the recognition of extracellular or intracellular pathogens (e.g., toll like receptors (TLRs)), and cell stressors (e.g., reactive oxygen species). More direct, aberrant protein expression also activates the NF-κB pathway (e.g., VHL loss) [26,40]. Upon stimulation, IκB is degraded or processed by proteasomes, which release NF-κB and subsequently cause NF-κB activation and its downstream gene transcription [41–43].

NF-κB hyper-activation can promote resistance to chemotherapy or cytokine treatments and correlates with a worse outcome in ccRCC [44–46]. Previous studies by others showed that hypoxia can induce NF-κB activation through the EglN2 negative regulation of IKKβ. NF-κB activity is also increased in VHL-deficient ccRCC [26,40,47]. ccRCC cells with VHL inactivation are resistant to TNF cytotoxicity, and their sensitivity to TNF can be restored by reconstituted wild-type VHL in these cells, at least partially through suppressing the NF-κB-dependent anti-apoptotic pathway [40]. Nevertheless, the way in which VHL regulates NF-κB activity remains unclear. One underlying mechanism is that VHL functions as an adaptor that promotes the inhibitory phosphorylation of the NF-κB agonist, Card9, by enhancing the interaction between Card 9 and CK2 in an HIF-independent fashion [26,40]. As a substrate recognition unit of an E3 ubiquitin ligase complex, it remains to be determined as to whether there are VHL substrates regulating NF-κB pathway activity in cancer.

The intersection between inflammation and cancer has recently blossomed. It has been demonstrated that tumor-promoting inflammation contributes to the acquisition of multiple hallmark chemicals that are needed for cancer initiation and progression, including growth factors that maintain cell proliferation (e.g., VEGF); survival factors that inhibit cell apoptosis (e.g., BCL2); extracellular matrix-modifying proteins that promotes angiogenesis, invasion, and metastasis (e.g., MMP); and other hallmark-promoting chemicals [32,48]. Cancer-promoting inflammation has been well established as a promising target [49–51]. Besides NF-κB, there are AP-1, CEBP, and JunB, etc., which are involved in both inflammation and hypoxia/VHL-related cancer progression [52,53]. The underlying molecular mechanisms of how hypoxia or VHL is linked to inflammation need to be clarified.

5. EglN3–VHL–EPOR Axis

Red blood cell production increases oxygen-carrying capacity and enables the body to survive harsh hypoxic conditions. For example, erythropoietin (EPO) stimulates erythropoietin receptor (EPOR)-JAK2-STAT5 signaling, which is responsible for cell proliferation and terminal differentiation into mature, oxygen-carrying red blood cells [54,55]. EPO is regulated by extrinsic EglN1-VHL-HIF signaling [56–58]. Heir et al. found that EPOR turnover is regulated by oxygen availability through intrinsic EglN3-VHL-EPOR signaling that is independent of HIF. Specifically, the proline 419 and 426 residues within the cytoplasmic region of EPOR are hydroxylated by EglN3, followed by VHL binding for polyubiquitination and proteasome degradation [59]. However, the functional roles of the EglN3–VHL–EPOR axis in hypoxic or VHL loss-of-function diseases remain to be determined in the future.

6. VHL–B-Myb Axis

B-Myb is a transcription factor that regulates the cell cycle and chromosomal condensation and stability [60,61]. Okumura et al. showed that B-Myb is targeted by VHL for ubiquitination and proteasome degradation, which can be prevented by the VEGF/platelet derived growth factor (PDGF)-induced T15 phosphorylation of B-Myb [62]. The authors showed that B-Myb depletion increases tumor growth by regulating different downstream genes from HIF and can antagonize

HIF-dependent tumorigenesis in an HIF-independent manner. The detailed molecular mechanism, however, needs to be clarified [62].

7. Other VHL Downstream Regulators

VHL may also play multiple roles in other various cell responses/diseases, including synaptogenesis (by targeting Filamin A (FLNA)), centrosome function (by targeting Cep68), and antiviral immune defense (by targeting mitochondrial antiviral signaling protein (MAVS)) through its E3 ubiquitin ligase protein activity in prolyl hydroxylation that can occur in dependent or independent pathways [63–65]. Specifically, PP5 and AURKA are targeted by VHL through oxygen-independent regulation [66,67]. MAVS and KLF4 are VHL substrates, but whether these regulations are dependent on oxygen availability is unknown [63,68]. The oxygen/VHL-mediated ubiquitination and proteasome degradation of proteins involve EGFR, atypical protein kinase C, Sprouty 2, β -adrenergic receptor II, Myb-binding protein 160, RPB1, RPB7, Cep68, Interleulin-32 β , CERKL, FLNA, and ERK5/BMK1 [64,65,69–79]. In addition, VHL transcriptionally regulates aldehyde dehydrogenase 2 (*ALDH2*) through the direct activation of transcription factor HNF-4 α in an HIF- and VHL E3 ligase-independent fashion, which contributes to the sensitivity of ccRCC cells to anthracycline treatment [80]. Although previous research suggested that ccRCC cell lines display constitutive active Notch signaling that is independent of VHL/HIF signaling [81], a very recent study demonstrated that VHL mutations affect vessel branching and maturation via Notch [28], though the underlying mechanism remains unknown. These substrates/regulators may provide new clues for a deeper understanding of the physiological and pathological functions of VHL.

8. VHL and Epigenetic Regulation

Most of these studies focus on the role of VHL/HIF activation on the proximal promoter of target genes. In recent years, the role of HIF on distant promoters and enhancers has gained more attention. For example, by using a chromosomal conformation assay with high-resolution analyses, Platt et al. recently found the long-range interactions between intergenic HIF binding regions and promoters of canonical *HIF* target genes [82]. However, these interactions did not seem to be affected by HIF activation through either hypoxia or VHL loss. HIF2 α was also reported to bind distant enhancers for Myc and Cyclin D1 to promote their transcription in ccRCC [83,84]. Yao et al. used paired primary patient tumor and normal samples, ccRCC cell lines, and normal kidney cell lines, followed by an extensive profiling of histone markers including H3K27Ac (marks active enhancer), H3K4me3 (marks active transcription in proximity to promoters), and H3K4me (marks enhancers) in ccRCC [85]. It is worth mentioning that they confirmed that 90% of tumors carried VHL loss-of-function mutations. First, they found that tumor-specific gained enhancers were associated with important oncogenic signaling and the hallmarks of ccRCC, including HIF1 α signaling and pro-angiogenesis pathways. Specifically, VEGFA, CXCR4, GLUT1, HK2, and PFKFB3 were all associated with gained enhancers. High resolution Capture-C also confirmed the distant interaction (100 kb) between VEGFA enhancer and its transcription starting site (TSS). In addition, they also identified the addition of super-enhancers in several potential novel oncogenes with VHL loss, including ZNF395. More importantly, their research demonstrated that VHL restoration largely leads to a diminished intensity in gained enhanced H3K27ac, indicating that these enhancers represent VHL-dependent epigenetic regulation in ccRCC. Furthermore, VHL-loss-mediated enhancer remodeling is mainly mediated by HIF2 α -HIF1 β -p300 signaling complexes. Accumulatively, this important research showed that the HIF2 α signaling complex may play an important role in VHL-mediated effects on enhancers that are important for ccRCC carcinogenesis.

VHL-loss-induced HIF regulates the expression of many histone lysine demethylases (KDMs) [86–89]. Therefore, it is likely that ccRCC, mostly with VHL loss, would demonstrate a distinctive histone modification. By using a multiplexed and high-resolution quantitative mass spectrometry approach, Chakraborty et al. found that ccRCC tumors with VHL loss preferentially

upregulate H3K27ac and H3K27me0/me1 levels [90]. More strikingly, VHL loss leads to the depletion of H3K27me3 due to increased H3K27 demethylase KDM6B activity in ccRCC cells. Since KDM6B is an *HIF* target gene [91], this study suggests that HIF-induced histone demethylase activity renders VHL-null ccRCC sensitive to H3K27 methyltransferase EZH1 inhibition. This important study will likely stimulate the development of EZH1-specific inhibitors for the treatment of ccRCC.

Hypoxia has been reported to upregulate G9a protein levels while not affecting their mRNA, indicating a potential post-transcriptional regulation of G9a by hypoxia [92]. However, the underlying mechanism remains unclear. In this latest study, Casciello et al. reported that G9a undergoes PHD1/EglN2-mediated prolyl hydroxylation, followed by its degradation via VHL [93]. Upon the treatment of hypoxia, G9a hydroxylation is inhibited and VHL cannot bind with G9a, which leads to its upregulation of protein levels. G9a is a major enzyme that converts unmodified H3 lysine 9 (H3K9) such that it becomes dimethylated. As a result, G9a accumulation leads to increased H3K9 dimethylation on a specific set of genes (including ARNTL and HHEX), which are essential for the function of tumor suppression under hypoxia. A G9a methyltransferase inhibitor, UNC0642, was used to test its efficacy in a syngeneic luminal breast cancer model, and it significantly reduced the tumor growth *in vivo* [94]. In summary, this paper showed that hypoxia, by regulating G9a protein levels and through the H3K9 dimethylation of key tumor suppressor promoters, contributes to an increased breast tumorigenesis. In theory, VHL loss is expected to increase G9a levels in ccRCC. It remains to be determined as to whether G9a can be used as a potential therapeutic target in ccRCC.

It is worth noting that the loss of VHL was reported to induce DNA replication stress and cause the accumulation of DNA damage that constrains cell proliferation and oncogenic transformation. However, the additional loss of the chromatin remodeling factor, PBRM1, in ccRCC, rescues this replication stress through the modulation of H3K9me3, therefore contributing to the oncogenic transformation in ccRCC [95]. It remains to be determined as to how VHL loss affects DNA replication stress.

9. Targeting VHL Signaling in ccRCC

While HIF1 α serves mainly as a tumor suppressor in kidney cancer [96,97], HIF2 α stabilization, as a result of VHL loss, is sufficient and necessary in the promotion of kidney tumor growth [98]. Therefore, HIF2 α serves as an important therapeutic target in kidney cancers that are related to *VHL* loss. However, HIF2 α has been called “undruggable” [99]. Previously, most of the therapeutic targeting strategies in VHL-null ccRCC have focused on using mTOR inhibitors (such as everolimus or temsirolimus) to inhibit HIF translation. Many therapeutic targeting strategies have also focused on the use of kinase inhibitors (including bevacizumab, sunitinib and sorafenib) to inhibit HIF downstream targets, including VEGF and PDGF, which has been reviewed extensively in previous publications [3]. Based on a high-throughput screening (HTS) and efforts in medicinal chemistry, recent studies have discovered a highly selective HIF2 α antagonist that does not affect HIF1 α signaling [100]. Follow-up studies have been carried out to test the drug-like HIF2 α chemical, PT2399, in ccRCC cell lines, cell-line-based orthotopic xenograft mouse models, a VHL-deficient metastatic setting, as well as RCC tumorgraft-bearing mice [101,102]. PT2399 selectively inhibits HIF2 α (but not HIF1 α) binding with ARNT, an essential co-factor for the transactivation of downstream target genes by HIF2 α for oncogenesis. As a result, PT2399 efficiently blocked ccRCC cell proliferation in a 3-D culture, tumor growth, and metastatic potential *in vivo*. More importantly, PT2399 displayed superior efficacy and better tolerability compared to current standard ccRCC therapy, such as sunitinib [102]. Therefore, the findings from these papers reveal the first potent HIF2 α inhibitor that can be optimized and potentially used in the treatment of ccRCC. PT2385, an analogue of PT2399, is now being tested in the Phase I clinical trial [103]. It is important to point out that not all VHL-deficient ccRCC cell lines demonstrate sensitivity to treatment with PT2399. It has also been shown that p53 mutations may be associated with an acquired resistance to PT2399 treatment [101]. Further investigations should be

carried out to identify predictive biomarkers for HIF2 α inhibitors in ccRCC, which may help validate these inhibitors in the clinical setting.

Although targeted therapies have been proven to be effective for certain tumors which express gain-of-function oncoproteins, therapeutic resistance eventually develops. It is possible to identify second-site targets that, when combined with a tumor specific mutation, cause a specific cancer cell death without affecting normal cells. This is called “synthetic lethality”, which has emerged as an important concept in cancer therapies [104,105]. Tumor-specific genetic alterations (such as VHL loss) reveal not only the biological changes that drive tumor progression but also vulnerabilities that can be exploited therapeutically. Since up to 90% of kidney tumors harbor VHL functional loss, it remains very attractive to identify synthetic lethality partners in VHL-loss kidney cancer while sparing normal cells.

By screening a small molecular library, Turcotte et al. identified STF-62247 as a promising compound that is selectively toxic toward VHL-deficient ccRCC cells [106]. Mechanistically, they identified that STF-62247 induces cell toxicity through autophagy and HIF-independent signaling. This discovery has stimulated a series of follow-up studies which focus on VHL deficiency as a target in ccRCC. In addition, there has been continuous interest in targeting VHL and HIF-dependent signaling in ccRCC. For example, STF-31 was found to specifically target VHL-loss ccRCC cells because it inhibits glucose uptake through Glut1, which is a canonical target of HIF signaling [107]. Chromomycin A3 was also identified to be toxic to VHL-deficient ccRCC cells because it acts as an HIF-dependent cytotoxin [108]. In addition, Rho-associated kinase 1 (ROCK1) was identified to be synthetically lethal with a VHL loss in an HIF-dependent manner [109]. The latest research on the selective toxicity of EZH1 inhibitors on VHL-null ccRCC cells also showed their dependency on HIF signaling [90]. On the other hand, there has been accumulating evidence suggesting that some of the synthetic lethality partners in VHL-loss tumors may not depend on HIF signaling. For example, a focused shRNA library screening identified that CDK6, MET, or MEK1 shRNAs may be selectively toxic to VHL-deficient ccRCC cells, but the effect is mediated in an HIF-independent fashion [110]. In addition, a highly sensitive high-throughput imaging-based platform with 12,800 small molecules identified homoharringtonine (HHT), an FDA-approved drug that may be used to treat chronic myeloid leukemia (CML), as a synthetic lethality partner in VHL-loss tumors [111]. However, it remains to be determined as to whether HHT affects HIF signaling in this setting. These new emerging targets/agents await to be further tested in potential future clinical trials.

10. Perspectives

Recently, proteolysis targeting chimeras (PROTACs) emerged as the new and powerful technology that can be used to target “undruggable” proteins for degradation [112]. PROTACs contain one moiety that binds an E3 ligase linked to another moiety that binds a desired cellular target protein. This induced proximity results in the ubiquitination of the target, followed by its degradation at the proteasome. VHL has been widely used as the E3 ligase adaptor for PROTAC. For example, there was a recent study that identified a specific TBK1 degrader by using VHL as the E3 ligase adaptor in PROTACs, which achieves the specific degradation of TBK1, but not its close family member IKK ϵ [113]. Therefore, it is promising that VHL can be used as a tool to degrade the “undruggable” targets in cancer that may achieve efficient therapeutic effects in cancer therapy.

11. Conclusions

While HIF and HIF-dependent signaling remain to be therapeutically interrogated in cancers with VHL loss, during the past few years, there have been several emerging studies that studied the role of VHL in the regulation of HIF-independent pathways. VHL can not only regulate other substrates (including NDRG3, G9a, and EpoR) through its canonical E3 ligase function, but also can be used as an adaptor protein that recruits the phosphatase pathway to mitigate constitutive AKT phosphorylation (Figure 1). It is an exciting time to study the multi-functionality of VHL in hypoxia signaling and cancer, which may yield additional therapeutic targets in cancer and other diseases.




Figure 1. Schematic of multi-functionality of VHL in hypoxia signaling and cancer.

Acknowledgments: Jing Zhang is supported by a DoD BCRP Breakthrough Fellowship Award (W81XWH-17-1-0016). Qing Zhang is supported by grants from the National Cancer Institute (R01CA211732, R21CA223675). Qing Zhang also received a career development award from the DoD (W81XWH-15-1-0599). Qing Zhang is a V Scholar, Kimmel Scholar, Komen Career Catalyst Awardee, and Mary Kay Foundation Awardee.

Author Contributions: Jing Zhang and Qing Zhang conceived and wrote this review together.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2016. *CA Cancer J. Clin.* **2016**, *66*, 7–30. [[CrossRef](#)] [[PubMed](#)]
2. Hsieh, J.J.; Purdue, M.P.; Signoretti, S.; Swanton, C.; Albiges, L.; Schmidinger, M.; Heng, D.Y.; Larkin, J.; Ficarra, V. Renal cell carcinoma. *Nat. Rev. Dis. Prim.* **2017**, *3*, 17009. [[CrossRef](#)] [[PubMed](#)]
3. Choueiri, T.K.; Motzer, R.J. Systemic therapy for metastatic renal-cell carcinoma. *N. Engl. J. Med.* **2017**, *376*, 354–366. [[CrossRef](#)] [[PubMed](#)]
4. Moore, L.E.; Nickerson, M.L.; Brennan, P.; Toro, J.R.; Jaeger, E.; Rinsky, J.; Han, S.S.; Zaridze, D.; Matveev, V.; Janout, V.; et al. Von hippel-lindau (vhl) inactivation in sporadic clear cell renal cancer: Associations with germline vhl polymorphisms and etiologic risk factors. *PLoS Genet.* **2011**, *7*, e1002312. [[CrossRef](#)] [[PubMed](#)]
5. Nickerson, M.L.; Jaeger, E.; Shi, Y.; Durocher, J.A.; Mahurkar, S.; Zaridze, D.; Matveev, V.; Janout, V.; Kollarova, H.; Bencko, V.; et al. Improved identification of von hippel-lindau gene alterations in clear cell renal tumors. *Clin. Cancer Res.* **2008**, *14*, 4726–4734. [[CrossRef](#)] [[PubMed](#)]
6. Sato, Y.; Yoshizato, T.; Shiraiishi, Y.; Maekawa, S.; Okuno, Y.; Kamura, T.; Shimamura, T.; Sato-Otsubo, A.; Nagae, G.; Suzuki, H.; et al. Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat. Genet.* **2013**, *45*, 860–867. [[CrossRef](#)] [[PubMed](#)]
7. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **2013**, *499*, 43–49.
8. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.* **2012**, *366*, 883–892. [[CrossRef](#)] [[PubMed](#)]
9. Kishida, T.; Stackhouse, T.M.; Chen, F.; Lerman, M.I.; Zbar, B. Cellular proteins that bind the von hippel-lindau disease gene product: Mapping of binding domains and the effect of missense mutations. *Cancer Res.* **1995**, *55*, 4544–4548. [[PubMed](#)]

10. Kibel, A.; Iliopoulos, O.; DeCaprio, J.A.; Kaelin, W.G., Jr. Binding of the von hippel-lindau tumor suppressor protein to elongin b and c. *Science* **1995**, *269*, 1444–1446. [[CrossRef](#)] [[PubMed](#)]
11. Duan, D.R.; Pause, A.; Burgess, W.H.; Aso, T.; Chen, D.Y.; Garrett, K.P.; Conaway, R.C.; Conaway, J.W.; Linehan, W.M.; Klausner, R.D. Inhibition of transcription elongation by the vhl tumor suppressor protein. *Science* **1995**, *269*, 1402–1406. [[CrossRef](#)] [[PubMed](#)]
12. Kaelin, W.G., Jr. Molecular basis of the vhl hereditary cancer syndrome. *Nat. Rev. Cancer* **2002**, *2*, 673–682. [[CrossRef](#)] [[PubMed](#)]
13. Jaakkola, P.; Mole, D.R.; Tian, Y.M.; Wilson, M.I.; Gielbert, J.; Gaskell, S.J.; von Kriegsheim, A.; Hebestreit, H.F.; Mukherji, M.; Schofield, C.J.; et al. Targeting of hif-alpha to the von hippel-lindau ubiquitylation complex by o₂-regulated prolyl hydroxylation. *Science* **2001**, *292*, 468–472. [[CrossRef](#)] [[PubMed](#)]
14. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J.M.; Lane, W.S.; Kaelin, W.G., Jr. Hifalpha targeted for vhl-mediated destruction by proline hydroxylation: Implications for O₂ sensing. *Science* **2001**, *292*, 464–468. [[CrossRef](#)] [[PubMed](#)]
15. Kaelin, W.G., Jr. How oxygen makes its presence felt. *Genes Dev.* **2002**, *16*, 1441–1445. [[CrossRef](#)] [[PubMed](#)]
16. Yang, H.; Kaelin, W.G., Jr. Molecular pathogenesis of the von hippel-lindau hereditary cancer syndrome: Implications for oxygen sensing. *Cell Growth Differ.* **2001**, *12*, 447–455. [[PubMed](#)]
17. Gossage, L.; Eisen, T.; Maher, E.R. Vhl, the story of a tumour suppressor gene. *Nat. Rev. Cancer* **2015**, *15*, 55–64. [[CrossRef](#)] [[PubMed](#)]
18. Semenza, G.L. Targeting HIF-1 for cancer therapy. *Nat. Rev. Cancer* **2003**, *3*, 721–732. [[CrossRef](#)] [[PubMed](#)]
19. Pugh, C.W.; Tan, C.C.; Jones, R.W.; Ratcliffe, P.J. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 10553–10557. [[CrossRef](#)] [[PubMed](#)]
20. Semenza, G.L.; Nejfelt, M.K.; Chi, S.M.; Antonarakis, S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. *Proc. Natl. Acad. Sci. USA* **1991**, *88*, 5680–5684. [[CrossRef](#)] [[PubMed](#)]
21. Choudhry, H.; Harris, A.L. Advances in hypoxia-inducible factor biology. *Cell Metab.* **2018**, *27*, 281–298. [[CrossRef](#)] [[PubMed](#)]
22. Hoffman, M.A.; Ohh, M.; Yang, H.; Klco, J.M.; Ivan, M.; Kaelin, W.G., Jr. Von hippel-lindau protein mutants linked to type 2c vhl disease preserve the ability to downregulate hif. *Hum. Mol. Genet.* **2001**, *10*, 1019–1027. [[CrossRef](#)] [[PubMed](#)]
23. Gordeuk, V.R.; Sergueeva, A.I.; Miasnikova, G.Y.; Okhotin, D.; Voloshin, Y.; Choyke, P.L.; Butman, J.A.; Jedlickova, K.; Prchal, J.T.; Polyakova, L.A. Congenital disorder of oxygen sensing: Association of the homozygous chuvaش polycythemia vhl mutation with thrombosis and vascular abnormalities but not tumors. *Blood* **2004**, *103*, 3924–3932. [[CrossRef](#)] [[PubMed](#)]
24. Clifford, S.C.; Cockman, M.E.; Smallwood, A.C.; Mole, D.R.; Woodward, E.R.; Maxwell, P.H.; Ratcliffe, P.J.; Maher, E.R. Contrasting effects on hif-1alpha regulation by disease-causing pvhl mutations correlate with patterns of tumourigenesis in von hippel-lindau disease. *Hum. Mol. Genet.* **2001**, *10*, 1029–1038. [[CrossRef](#)] [[PubMed](#)]
25. Calzada, M.J.; Esteban, M.A.; Feijoo-Cuaresma, M.; Castellanos, M.C.; Naranjo-Suarez, S.; Temes, E.; Mendez, F.; Yanez-Mo, M.; Ohh, M.; Landazuri, M.O. Von hippel-lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. *Cancer Res.* **2006**, *66*, 1553–1560. [[CrossRef](#)] [[PubMed](#)]
26. Yang, H.; Minamishima, Y.A.; Yan, Q.; Schlissio, S.; Ebert, B.L.; Zhang, X.; Zhang, L.; Kim, W.Y.; Olumi, A.F.; Kaelin, W.G., Jr. PVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappab agonist Card9 by CK2. *Mol. Cell* **2007**, *28*, 15–27. [[CrossRef](#)] [[PubMed](#)]
27. Guo, J.; Chakraborty, A.A.; Liu, P.; Gan, W.; Zheng, X.; Inuzuka, H.; Wang, B.; Zhang, J.; Zhang, L.; Yuan, M.; et al. PVHL suppresses kinase activity of akt in a proline-hydroxylation-dependent manner. *Science* **2016**, *353*, 929–932. [[CrossRef](#)] [[PubMed](#)]
28. Arreola, A.; Payne, L.B.; Julian, M.H.; de Cubas, A.A.; Daniels, A.B.; Taylor, S.; Zhao, H.; Darden, J.; Bautch, V.L.; Rathmell, W.K.; et al. Von hippel-lindau mutations disrupt vascular patterning and maturation via notch. *JCI Insight* **2018**, *3*. [[CrossRef](#)] [[PubMed](#)]
29. Zurlo, G.; Guo, J.; Takada, M.; Wei, W.; Zhang, Q. New insights into protein hydroxylation and its important role in human diseases. *Biochim. Biophys. Acta* **2016**, *1866*, 208–220. [[CrossRef](#)] [[PubMed](#)]

30. Lee, D.C.; Sohn, H.A.; Park, Z.Y.; Oh, S.; Kang, Y.K.; Lee, K.M.; Kang, M.; Jang, Y.J.; Yang, S.J.; Hong, Y.K.; et al. A lactate-induced response to hypoxia. *Cell* **2015**, *161*, 595–609. [CrossRef] [PubMed]
31. Park, K.C.; Lee, D.C.; Yeom, Y.I. Ndrg3-mediated lactate signaling in hypoxia. *BMB Rep.* **2015**, *48*, 301–302. [CrossRef] [PubMed]
32. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. *Cell* **2011**, *144*, 646–674. [CrossRef] [PubMed]
33. Guzy, R.D.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K.D.; Simon, M.C.; Hammerling, U.; Schumacker, P.T. Mitochondrial complex iii is required for hypoxia-induced ros production and cellular oxygen sensing. *Cell Metab.* **2005**, *1*, 401–408. [CrossRef] [PubMed]
34. Nakazawa, M.S.; Keith, B.; Simon, M.C. Oxygen availability and metabolic adaptations. *Nat. Rev. Cancer* **2016**, *16*, 663–673. [CrossRef] [PubMed]
35. Hakimi, A.A.; Reznik, E.; Lee, C.H.; Creighton, C.J.; Brannon, A.R.; Luna, A.; Aksoy, B.A.; Liu, E.M.; Shen, R.; Lee, W.; et al. An integrated metabolic atlas of clear cell renal cell carcinoma. *Cancer Cell* **2016**, *29*, 104–116. [CrossRef] [PubMed]
36. Manning, B.D.; Toker, A. AKT/PKB signaling: Navigating the network. *Cell* **2017**, *169*, 381–405. [CrossRef] [PubMed]
37. Polytarchou, C.; Iliopoulos, D.; Hatziapostolou, M.; Kottakis, F.; Maroulakou, I.; Struhl, K.; Tsichlis, P.N. Akt2 regulates all akt isoforms and promotes resistance to hypoxia through induction of mir-21 upon oxygen deprivation. *Cancer Res.* **2011**, *71*, 4720–4731. [CrossRef] [PubMed]
38. Chae, Y.C.; Vaira, V.; Caino, M.C.; Tang, H.Y.; Seo, J.H.; Kossenkov, A.V.; Ottobrini, L.; Martelli, C.; Lucignani, G.; Bertolini, I.; et al. Mitochondrial akt regulation of hypoxic tumor reprogramming. *Cancer Cell* **2016**, *30*, 257–272. [CrossRef] [PubMed]
39. Zhang, Y.; Kwok-Shing Ng, P.; Kucherlapati, M.; Chen, F.; Liu, Y.; Tsang, Y.H.; de Velasco, G.; Jeong, K.J.; Akbani, R.; Hadjipanayis, A.; et al. A pan-cancer proteogenomic atlas of pi3k/akt/mTOR pathway alterations. *Cancer Cell* **2017**, *31*, 820–832.e3. [CrossRef] [PubMed]
40. Qi, H.; Ohh, M. The von hippel-lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappab-dependent antiapoptotic pathway. *Cancer Res.* **2003**, *63*, 7076–7080. [PubMed]
41. Ghosh, S.; Hayden, M.S. Celebrating 25 years of nf-kappab research. *Immunol. Rev.* **2012**, *246*, 5–13. [CrossRef] [PubMed]
42. Rinkenbaugh, A.L.; Baldwin, A.S. The NF-kappab pathway and cancer stem cells. *Cells* **2016**, *5*, 16. [CrossRef] [PubMed]
43. Baldwin, A.S. Regulation of cell death and autophagy by IKK and NF-kappab: Critical mechanisms in immune function and cancer. *Immunol. Rev.* **2012**, *246*, 327–345. [CrossRef] [PubMed]
44. Oya, M.; Takayanagi, A.; Horiguchi, A.; Mizuno, R.; Ohtsubo, M.; Marumo, K.; Shimizu, N.; Murai, M. Increased nuclear factor-kappa b activation is related to the tumor development of renal cell carcinoma. *Carcinogenesis* **2003**, *24*, 377–384. [CrossRef] [PubMed]
45. Peri, S.; Devarajan, K.; Yang, D.H.; Knudson, A.G.; Balachandran, S. Meta-analysis identifies nf-kappab as a therapeutic target in renal cancer. *PLoS ONE* **2013**, *8*, e76746. [CrossRef] [PubMed]
46. Sourbier, C.; Danilin, S.; Lindner, V.; Steger, J.; Rothhut, S.; Meyer, N.; Jacqmin, D.; Helwig, J.J.; Lang, H.; Massfelder, T. Targeting the nuclear factor-kappab rescue pathway has promising future in human renal cell carcinoma therapy. *Cancer Res.* **2007**, *67*, 11668–11676. [CrossRef] [PubMed]
47. Cummins, E.P.; Berra, E.; Comerford, K.M.; Ginouves, A.; Fitzgerald, K.T.; Seeballuck, F.; Godson, C.; Nielsen, J.E.; Moynagh, P.; Pouyssegur, J.; et al. Prolyl hydroxylase-1 negatively regulates ikappab kinase-beta, giving insight into hypoxia-induced nfkappab activity. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 18154–18159. [CrossRef] [PubMed]
48. Nakanishi, C.; Toi, M. Nuclear factor-kappab inhibitors as sensitizers to anticancer drugs. *Nat. Rev. Cancer* **2005**, *5*, 297–309. [CrossRef] [PubMed]
49. Rayburn, E.R.; Ezell, S.J.; Zhang, R. Anti-inflammatory agents for cancer therapy. *Mol. Cell. Pharmacol.* **2009**, *1*, 29–43. [CrossRef] [PubMed]
50. Todoric, J.; Antonucci, L.; Karin, M. Targeting inflammation in cancer prevention and therapy. *Cancer Prev. Res. (Phila)* **2016**, *9*, 895–905. [CrossRef] [PubMed]

51. Marelli, G.; Sica, A.; Vannucci, L.; Allavena, P. Inflammation as target in cancer therapy. *Curr. Opin. Pharmacol.* **2017**, *35*, 57–65. [[CrossRef](#)] [[PubMed](#)]
52. Kanno, T.; Kamba, T.; Yamasaki, T.; Shibasaki, N.; Saito, R.; Terada, N.; Toda, Y.; Mikami, Y.; Inoue, T.; Kanematsu, A.; et al. Junb promotes cell invasion and angiogenesis in vhl-defective renal cell carcinoma. *Oncogene* **2012**, *31*, 3098–3110. [[CrossRef](#)] [[PubMed](#)]
53. Cummins, E.P.; Taylor, C.T. Hypoxia-responsive transcription factors. *Pflugers Arch.* **2005**, *450*, 363–371. [[CrossRef](#)] [[PubMed](#)]
54. Witthuhn, B.A.; Quelle, F.W.; Silvennoinen, O.; Yi, T.; Tang, B.; Miura, O.; Ihle, J.N. Jak2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. *Cell* **1993**, *74*, 227–236. [[CrossRef](#)]
55. Wu, H.; Liu, X.; Jaenisch, R.; Lodish, H.F. Generation of committed erythroid bfu-e and cfu-e progenitors does not require erythropoietin or the erythropoietin receptor. *Cell* **1995**, *83*, 59–67. [[CrossRef](#)]
56. Gruber, M.; Hu, C.J.; Johnson, R.S.; Brown, E.J.; Keith, B.; Simon, M.C. Acute postnatal ablation of hif-2alpha results in anemia. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 2301–2306. [[CrossRef](#)] [[PubMed](#)]
57. Rankin, E.B.; Biju, M.P.; Liu, Q.; Unger, T.L.; Rha, J.; Johnson, R.S.; Simon, M.C.; Keith, B.; Haase, V.H. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. *J. Clin. Investig.* **2007**, *117*, 1068–1077. [[CrossRef](#)] [[PubMed](#)]
58. Arsenault, P.R.; Pei, F.; Lee, R.; Kerestes, H.; Percy, M.J.; Keith, B.; Simon, M.C.; Lappin, T.R.; Khurana, T.S.; Lee, F.S. A knock-in mouse model of human PHD2 gene-associated erythrocytosis establishes a haploinsufficiency mechanism. *J. Biol. Chem.* **2013**, *288*, 33571–33584. [[CrossRef](#)] [[PubMed](#)]
59. Heir, P.; Srikumar, T.; Bikopoulos, G.; Bunda, S.; Poon, B.P.; Lee, J.E.; Raught, B.; Ohh, M. Oxygen-dependent regulation of erythropoietin receptor turnover and signaling. *J. Biol. Chem.* **2016**, *291*, 7357–7372. [[CrossRef](#)] [[PubMed](#)]
60. Sala, A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. *Eur. J. Cancer* **2005**, *41*, 2479–2484. [[CrossRef](#)] [[PubMed](#)]
61. Manak, J.R.; Wen, H.; Van, T.; Andrejka, L.; Lipsick, J.S. Loss of drosophila myb interrupts the progression of chromosome condensation. *Nat. Cell Biol.* **2007**, *9*, 581–587. [[CrossRef](#)] [[PubMed](#)]
62. Okumura, F.; Uematsu, K.; Byrne, S.D.; Hirano, M.; Joo-Okumura, A.; Nishikimi, A.; Shuin, T.; Fukui, Y.; Nakatsukasa, K.; Kamura, T. Parallel regulation of von hippel-lindau disease by pvhl-mediated degradation of b-myb and hypoxia-inducible factor alpha. *Mol. Cell. Biol.* **2016**, *36*, 1803–1817. [[CrossRef](#)] [[PubMed](#)]
63. Du, J.; Zhang, D.; Zhang, W.; Ouyang, G.; Wang, J.; Liu, X.; Li, S.; Ji, W.; Liu, W.; Xiao, W. Pvhl negatively regulates antiviral signaling by targeting mavs for proteasomal degradation. *J. Immunol.* **2015**, *195*, 1782–1790. [[CrossRef](#)] [[PubMed](#)]
64. Segura, I.; Lange, C.; Knevels, E.; Moskalyuk, A.; Pulizzi, R.; Eelen, G.; Chaze, T.; Tudor, C.; Boulegue, C.; Holt, M.; et al. The oxygen sensor phd2 controls dendritic spines and synapses via modification of filamin A. *Cell Rep.* **2016**, *14*, 2653–2667. [[CrossRef](#)] [[PubMed](#)]
65. Yin, H.; Zheng, L.; Liu, W.; Zhang, D.; Li, W.; Yuan, L. Rootletin prevents Cep68 from VHL-mediated proteasomal degradation to maintain centrosome cohesion. *Biochim. Biophys. Acta* **2017**, *1864*, 645–654. [[CrossRef](#)] [[PubMed](#)]
66. Dushukyan, N.; Dunn, D.M.; Sager, R.A.; Woodford, M.R.; Loiselle, D.R.; Daneshvar, M.; Baker-Williams, A.J.; Chisholm, J.D.; Truman, A.W.; Vaughan, C.K.; et al. Phosphorylation and ubiquitination regulate protein phosphatase 5 activity and its prosurvival role in kidney cancer. *Cell Rep.* **2017**, *21*, 1883–1895. [[CrossRef](#)] [[PubMed](#)]
67. Hasanov, E.; Chen, G.; Chowdhury, P.; Weldon, J.; Ding, Z.; Jonasch, E.; Sen, S.; Walker, C.L.; Dere, R. Ubiquitination and regulation of aurka identifies a hypoxia-independent e3 ligase activity of vhl. *Oncogene* **2017**, *36*, 3450–3463. [[CrossRef](#)] [[PubMed](#)]
68. Gamper, A.M.; Qiao, X.; Kim, J.; Zhang, L.; DeSimone, M.C.; Rathmell, W.K.; Wan, Y. Regulation of klf4 turnover reveals an unexpected tissue-specific role of pvhl in tumorigenesis. *Mol. Cell* **2012**, *45*, 233–243. [[CrossRef](#)] [[PubMed](#)]
69. Kuznetsova, A.V.; Meller, J.; Schnell, P.O.; Nash, J.A.; Ignacak, M.L.; Sanchez, Y.; Conaway, J.W.; Conaway, R.C.; Czyzyk-Krzeska, M.F. Von hippel-lindau protein binds hyperphosphorylated large subunit of rna polymerase ii through a proline hydroxylation motif and targets it for ubiquitination. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 2706–2711. [[CrossRef](#)] [[PubMed](#)]

70. Mikhaylova, O.; Ignacak, M.L.; Barankiewicz, T.J.; Harbaugh, S.V.; Yi, Y.; Maxwell, P.H.; Schneider, M.; Van Geyte, K.; Carmeliet, P.; Revelo, M.P.; et al. The von hippel-lindau tumor suppressor protein and egl-9-type proline hydroxylases regulate the large subunit of rna polymerase ii in response to oxidative stress. *Mol. Cell. Biol.* **2008**, *28*, 2701–2717. [CrossRef] [PubMed]
71. Okuda, H.; Saitoh, K.; Hirai, S.; Iwai, K.; Takaki, Y.; Baba, M.; Minato, N.; Ohno, S.; Shuin, T. The von hippel-lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase c. *J. Biol. Chem.* **2001**, *276*, 43611–43617. [CrossRef] [PubMed]
72. Anderson, K.; Nordquist, K.A.; Gao, X.; Hicks, K.C.; Zhai, B.; Gygi, S.P.; Patel, T.B. Regulation of cellular levels of sprouty2 protein by prolyl hydroxylase domain and von hippel-lindau proteins. *J. Biol. Chem.* **2011**, *286*, 42027–42036. [CrossRef] [PubMed]
73. Zhou, L.; Yang, H. The von hippel-lindau tumor suppressor protein promotes c-cbl-independent poly-ubiquitylation and degradation of the activated egfr. *PLoS ONE* **2011**, *6*, e23936. [CrossRef] [PubMed]
74. Xie, L.; Xiao, K.; Whalen, E.J.; Forrester, M.T.; Freeman, R.S.; Fong, G.; Gygi, S.P.; Lefkowitz, R.J.; Stamler, J.S. Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by egln3 and ubiquitylation by pvhl. *Sci. Signal.* **2009**, *2*, ra33. [CrossRef] [PubMed]
75. Lai, Y.; Qiao, M.; Song, M.; Weintraub, S.T.; Shiio, Y. Quantitative proteomics identifies the myb-binding protein p160 as a novel target of the von hippel-lindau tumor suppressor. *PLoS ONE* **2011**, *6*, e16975. [CrossRef] [PubMed]
76. Na, X.; Duan, H.O.; Messing, E.M.; Schoen, S.R.; Ryan, C.K.; di Sant’Agnese, P.A.; Golemis, E.A.; Wu, G. Identification of the RNA polymerase ii subunit hsRPB7 as a novel target of the von hippel-lindau protein. *EMBO J.* **2003**, *22*, 4249–4259. [CrossRef] [PubMed]
77. Yong, H.J.; Park, J.S.; Lee Jeong, A.; Han, S.; Lee, S.; Ka, H.I.; Sumiyasuren, B.; Joo, H.J.; So, S.J.; Park, J.Y.; et al. Von hippel-lindau regulates interleukin-32beta stability in ovarian cancer cells. *Oncotarget* **2017**, *8*, 69833–69846. [CrossRef] [PubMed]
78. Chen, J.; Liu, F.; Li, H.; Archacki, S.; Gao, M.; Liu, Y.; Liao, S.; Huang, M.; Wang, J.; Yu, S.; et al. Pvhl interacts with ceramide kinase like (cerkl) protein and ubiquitinates it for oxygen dependent proteasomal degradation. *Cell. Signal.* **2015**, *27*, 2314–2323. [CrossRef] [PubMed]
79. Arias-Gonzalez, L.; Moreno-Gimeno, I.; del Campo, A.R.; Serrano-Oviedo, L.; Valero, M.L.; Esparis-Ogando, A.; de la Cruz-Morcillo, M.A.; Melgar-Rojas, P.; Garcia-Cano, J.; Cimas, F.J.; et al. Erk5/bmk1 is a novel target of the tumor suppressor vhl: Implication in clear cell renal carcinoma. *Neoplasia* **2013**, *15*, 649–659. [CrossRef] [PubMed]
80. Gao, Y.H.; Wu, Z.X.; Xie, L.Q.; Li, C.X.; Mao, Y.Q.; Duan, Y.T.; Han, B.; Han, S.F.; Yu, Y.; Lu, H.J.; et al. Vhl deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating aldh2. *Nat. Commun.* **2017**, *8*, 15337. [CrossRef] [PubMed]
81. Sjolund, J.; Johansson, M.; Manna, S.; Norin, C.; Pietras, A.; Beckman, S.; Nilsson, E.; Ljungberg, B.; Axelson, H. Suppression of renal cell carcinoma growth by inhibition of notch signaling in vitro and in vivo. *J. Clin. Investigig.* **2008**, *118*, 217–228. [CrossRef] [PubMed]
82. Platt, J.L.; Salama, R.; Smythies, J.; Choudhry, H.; Davies, J.O.; Hughes, J.R.; Ratcliffe, P.J.; Mole, D.R. Capture-c reveals preformed chromatin interactions between hif-binding sites and distant promoters. *EMBO Rep.* **2016**, *17*, 1410–1421. [CrossRef] [PubMed]
83. Grampp, S.; Platt, J.L.; Lauer, V.; Salama, R.; Kranz, F.; Neumann, V.K.; Wach, S.; Stohr, C.; Hartmann, A.; Eckardt, K.U.; et al. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects hif binding to a myc enhancer. *Nat. Commun.* **2016**, *7*, 13183. [CrossRef] [PubMed]
84. Schodel, J.; Bardella, C.; Sciesielski, L.K.; Brown, J.M.; Pugh, C.W.; Buckle, V.; Tomlinson, I.P.; Ratcliffe, P.J.; Mole, D.R. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of hif to an enhancer of cyClin. d1 expression. *Nat. Genet.* **2012**, *44*, 420–425. [CrossRef] [PubMed]
85. Yao, X.; Tan, J.; Lim, K.J.; Koh, J.; Ooi, W.F.; Li, Z.; Huang, D.; Xing, M.; Chan, Y.S.; Qu, J.Z.; et al. Vhl deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. *Cancer Discov.* **2017**, *7*, 1284–1305. [CrossRef] [PubMed]
86. Xia, X.; Lemieux, M.E.; Li, W.; Carroll, J.S.; Brown, M.; Liu, X.S.; Kung, A.L. Integrative analysis of hif binding and transactivation reveals its role in maintaining histone methylation homeostasis. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 4260–4265. [CrossRef] [PubMed]

87. Pollard, P.J.; Loenarz, C.; Mole, D.R.; McDonough, M.A.; Gleadle, J.M.; Schofield, C.J.; Ratcliffe, P.J. Regulation of jumonji-domain-containing histone demethylases by hypoxia-inducible factor (hif)-1alpha. *Biochem. J.* **2008**, *416*, 387–394. [CrossRef] [PubMed]
88. Beyer, S.; Kristensen, M.M.; Jensen, K.S.; Johansen, J.V.; Staller, P. The histone demethylases jmjd1a and jmjd2b are transcriptional targets of hypoxia-inducible factor hif. *J. Biol. Chem.* **2008**, *283*, 36542–36552. [CrossRef] [PubMed]
89. Krieg, A.J.; Rankin, E.B.; Chan, D.; Razorenova, O.; Fernandez, S.; Giaccia, A.J. Regulation of the histone demethylase jmjd1a by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. *Mol. Cell. Biol.* **2010**, *30*, 344–353. [CrossRef] [PubMed]
90. Chakraborty, A.A.; Nakamura, E.; Qi, J.; Creech, A.; Jaffe, J.D.; Paulk, J.; Novak, J.S.; Nagulapalli, K.; McBrayer, S.K.; Cowley, G.S.; et al. Hif activation causes synthetic lethality between the vhl tumor suppressor and the ezh1 histone methyltransferase. *Sci. Transl. Med.* **2017**, *9*. [CrossRef] [PubMed]
91. Lee, H.Y.; Choi, K.; Oh, H.; Park, Y.K.; Park, H. Hif-1-dependent induction of jumonji domain-containing protein (jmjd) 3 under hypoxic conditions. *Mol. Cells* **2014**, *37*, 43–50. [CrossRef] [PubMed]
92. Chen, H.; Yan, Y.; Davidson, T.L.; Shinkai, Y.; Costa, M. Hypoxic stress induces dimethylated histone h3 lysine 9 through histone methyltransferase g9a in mammalian cells. *Cancer Res.* **2006**, *66*, 9009–9016. [CrossRef] [PubMed]
93. Casciello, F.; Al-Ejeh, F.; Kelly, G.; Brennan, D.J.; Ngiow, S.F.; Young, A.; Stoll, T.; Windloch, K.; Hill, M.M.; Smyth, M.J.; et al. G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, 7077–7082. [CrossRef] [PubMed]
94. Liu, F.; Barsyte-Lovejoy, D.; Li, F.; Xiong, Y.; Korboukh, V.; Huang, X.P.; Allali-Hassani, A.; Janzen, W.P.; Roth, B.L.; Frye, S.V.; et al. Discovery of an in vivo chemical probe of the lysine methyltransferases g9a and glp. *J. Med. Chem.* **2013**, *56*, 8931–8942. [CrossRef] [PubMed]
95. Espana-Agusti, J.; Warren, A.; Chew, S.K.; Adams, D.J.; Matakidou, A. Loss of pbrm1 rescues vhl dependent replication stress to promote renal carcinogenesis. *Nat. Commun.* **2017**, *8*, 2026. [CrossRef] [PubMed]
96. Shen, C.; Beroukhim, R.; Schumacher, S.E.; Zhou, J.; Chang, M.; Signoretti, S.; Kaelin, W.G., Jr. Genetic and functional studies implicate hif1alpha as a 14q kidney cancer suppressor gene. *Cancer Discov.* **2011**, *1*, 222–235. [CrossRef] [PubMed]
97. Gordan, J.D.; Lal, P.; Dondeti, V.R.; Letrero, R.; Parekh, K.N.; Oquendo, C.E.; Greenberg, R.A.; Flaherty, K.T.; Rathmell, W.K.; Keith, B.; et al. Hif-alpha effects on c-myc distinguish two subtypes of sporadic vhl-deficient clear cell renal carcinoma. *Cancer Cell* **2008**, *14*, 435–446. [CrossRef] [PubMed]
98. Kondo, K.; Kim, W.Y.; Lechpmammer, M.; Kaelin, W.G., Jr. Inhibition of hif2alpha is sufficient to suppress pvhf-defective tumor growth. *PLoS Biol.* **2003**, *1*, E83. [CrossRef] [PubMed]
99. Koehler, A.N. A complex task? Direct modulation of transcription factors with small molecules. *Curr. Opin. Chem. Biol.* **2010**, *14*, 331–340. [CrossRef] [PubMed]
100. Scheuermann, T.H.; Li, Q.; Ma, H.W.; Key, J.; Zhang, L.; Chen, R.; Garcia, J.A.; Naidoo, J.; Longgood, J.; Frantz, D.E.; et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. *Nat. Chem. Biol.* **2013**, *9*, 271–276. [CrossRef] [PubMed]
101. Cho, H.; Du, X.; Rizzi, J.P.; Liberzon, E.; Chakraborty, A.A.; Gao, W.; Carvo, I.; Signoretti, S.; Bruick, R.K.; Josey, J.A.; et al. On-target efficacy of a hif-2alpha antagonist in preclinical kidney cancer models. *Nature* **2016**, *539*, 107–111. [CrossRef] [PubMed]
102. Chen, W.; Hill, H.; Christie, A.; Kim, M.S.; Holloman, E.; Pavia-Jimenez, A.; Homayoun, F.; Ma, Y.; Patel, N.; Yell, P.; et al. Targeting renal cell carcinoma with a hif-2 antagonist. *Nature* **2016**, *539*, 112–117. [CrossRef] [PubMed]
103. Courtney, K.D.; Infante, J.R.; Lam, E.T.; Figlin, R.A.; Rini, B.I.; Brugarolas, J.; Zojwalla, N.J.; Lowe, A.M.; Wang, K.; Wallace, E.M.; et al. Phase i dose-escalation trial of pt2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. *J. Clin. Oncol.* **2017**. [CrossRef]
104. O’Neil, N.J.; Bailey, M.L.; Hieter, P. Synthetic lethality and cancer. *Nat. Rev. Genet.* **2017**, *18*, 613–623. [CrossRef] [PubMed]
105. Kaelin, W.G., Jr. The concept of synthetic lethality in the context of anticancer therapy. *Nat. Rev. Cancer* **2005**, *5*, 689–698. [CrossRef] [PubMed]

106. Turcotte, S.; Chan, D.A.; Sutphin, P.D.; Hay, M.P.; Denny, W.A.; Giaccia, A.J. A molecule targeting vhl-deficient renal cell carcinoma that induces autophagy. *Cancer Cell* **2008**, *14*, 90–102. [[CrossRef](#)] [[PubMed](#)]
107. Chan, D.A.; Sutphin, P.D.; Nguyen, P.; Turcotte, S.; Lai, E.W.; Banh, A.; Reynolds, G.E.; Chi, J.T.; Wu, J.; Solow-Cordero, D.E.; et al. Targeting glut1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. *Sci. Transl. Med.* **2011**, *3*, 94ra70. [[CrossRef](#)] [[PubMed](#)]
108. Sutphin, P.D.; Chan, D.A.; Li, J.M.; Turcotte, S.; Krieg, A.J.; Giaccia, A.J. Targeting the loss of the von hippel-lindau tumor suppressor gene in renal cell carcinoma cells. *Cancer Res.* **2007**, *67*, 5896–5905. [[CrossRef](#)] [[PubMed](#)]
109. Thompson, J.M.; Nguyen, Q.H.; Singh, M.; Pavesic, M.W.; Nesterenko, I.; Nelson, L.J.; Liao, A.C.; Razorenova, O.V. Rho-associated kinase 1 inhibition is synthetically lethal with von hippel-lindau deficiency in clear cell renal cell carcinoma. *Oncogene* **2017**, *36*, 1080–1089. [[CrossRef](#)] [[PubMed](#)]
110. Bommi-Reddy, A.; Almeciga, I.; Sawyer, J.; Geisen, C.; Li, W.; Harlow, E.; Kaelin, W.G., Jr.; Grueneberg, D.A. Kinase requirements in human cells: Iii. Altered kinase requirements in vhl^{-/-} cancer cells detected in a pilot synthetic lethal screen. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 16484–16489. [[CrossRef](#)] [[PubMed](#)]
111. Wolff, N.C.; Pavia-Jimenez, A.; Tcheuyap, V.T.; Alexander, S.; Vishwanath, M.; Christie, A.; Xie, X.J.; Williams, N.S.; Kapur, P.; Posner, B.; et al. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von hippel-lindau loss in renal cell carcinoma. *Oncotarget* **2015**, *6*, 16951–16962. [[CrossRef](#)] [[PubMed](#)]
112. Lai, A.C.; Crews, C.M. Induced protein degradation: An emerging drug discovery paradigm. *Nat. Rev. Drug Discov.* **2017**, *16*, 101–114. [[CrossRef](#)] [[PubMed](#)]
113. Crew, A.P.; Raina, K.; Dong, H.; Qian, Y.; Wang, J.; Vigil, D.; Serebrenik, Y.V.; Hamman, B.D.; Morgan, A.; Ferraro, C.; et al. Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (protacs) of tank-binding kinase 1. *J. Med. Chem.* **2018**, *61*, 583–598. [[CrossRef](#)] [[PubMed](#)]



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).